- Home
- CEE vs STTK Comparison
CEE vs STTK Comparison
Compare CEE & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEE
- STTK
- Stock Information
- Founded
- CEE 1990
- STTK 2016
- Country
- CEE Germany
- STTK United States
- Employees
- CEE N/A
- STTK N/A
- Industry
- CEE Finance Companies
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- CEE Finance
- STTK Health Care
- Exchange
- CEE Nasdaq
- STTK Nasdaq
- Market Cap
- CEE 105.5M
- STTK 112.6M
- IPO Year
- CEE N/A
- STTK 2020
- Fundamental
- Price
- CEE $15.86
- STTK $1.95
- Analyst Decision
- CEE
- STTK Hold
- Analyst Count
- CEE 0
- STTK 5
- Target Price
- CEE N/A
- STTK $3.00
- AVG Volume (30 Days)
- CEE 22.0K
- STTK 376.3K
- Earning Date
- CEE 01-01-0001
- STTK 11-13-2025
- Dividend Yield
- CEE 3.86%
- STTK N/A
- EPS Growth
- CEE N/A
- STTK N/A
- EPS
- CEE N/A
- STTK N/A
- Revenue
- CEE N/A
- STTK $2,997,000.00
- Revenue This Year
- CEE N/A
- STTK N/A
- Revenue Next Year
- CEE N/A
- STTK N/A
- P/E Ratio
- CEE N/A
- STTK N/A
- Revenue Growth
- CEE N/A
- STTK N/A
- 52 Week Low
- CEE $7.80
- STTK $0.69
- 52 Week High
- CEE $10.32
- STTK $2.71
- Technical
- Relative Strength Index (RSI)
- CEE 54.09
- STTK 50.69
- Support Level
- CEE $15.41
- STTK $1.78
- Resistance Level
- CEE $16.07
- STTK $2.08
- Average True Range (ATR)
- CEE 0.43
- STTK 0.19
- MACD
- CEE 0.07
- STTK -0.03
- Stochastic Oscillator
- CEE 80.15
- STTK 43.48
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.